Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) traded down 9% during trading on Wednesday . The stock traded as low as GBX 227 ($3.08) and last traded at GBX 229.65 ($3.12). 73,022 shares changed hands during mid-day trading, an increase of 63% from the average session volume of 44,782 shares. The stock had previously closed at GBX 252.50 ($3.43).
Faron Pharmaceuticals Oy Stock Performance
The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The firm's 50-day moving average is GBX 219.01 and its two-hundred day moving average is GBX 192.58. The stock has a market cap of £283.94 million, a P/E ratio of -5.66 and a beta of 0.36.
Insiders Place Their Bets
In related news, insider Markku Jalkanen sold 600,000 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of GBX 310 ($4.21), for a total transaction of £1,860,000 ($2,525,801.20). Insiders own 31.82% of the company's stock.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Stories
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
